Slide 1: Q4 & FY 2025 Earnings Call Presentation
Q4 & FY 2025 Earnings Call Presentation March │ 2026 1
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Auna S.A. (“Auna” or the “Company”) solely for use at this presentation. This presentation is confidential to the recipient. Accordingly, any attempt to copy, summarize or distribute this presentation or any portion hereof in any form to any other pa
Slide 3: Today's Speakers
Today’s Speakers +30 +20 +25 Jesus Zamora Gisele Remy Lorenzo Massart Executive Chairman of the Board and Chief Financial Officer and Executive Vice President, Strategy and President Executive Vice President Equity Capital Markets • Member of the Board since 2008 and President • Chief Financial Offi
Slide 4: 4Q'25 and FY25 Highlights
4Q’25 and FY25 Highlights1 “Results were in 4Q’24 Adjusted EBITDA2 -14% FXN2 YoY with 19.5% margin, -4.5p.p. vs 4Q’24. FY25 Adjusted EBITDA2 -3% FXN YoY with 20.9% margin -1.7p.p vs 22.6% in FY24. line with our Reported results impacted by depreciation of PEN/MXN (-1%) and appreciation of PEN/COP (3
Slide 5: Strong Performance in Peru and Resilience in Colombia, With Signs of Recovery in Mexico
Strong Performance in Peru and Resilience in Colombia, With Signs of Recovery in Mexico Consolidated 4Q25 Consolidated FY25 Revenue (S/) Adjusted EBITDA(1) (S/) Revenue (S/) Adjusted EBITDA (1) (S/) 1,133 Mn 220 Mn 4,385 Mn 917 Mn +7% -13% +0% -8% +6% FXN YoY -14% FXN YoY +4% FXN YoY -3% FXN YoY Hea
Slide 6: Q4 and FY 2025 Results by Segment
Q4 and FY 2025 Results by Segment 6
Slide 7: Healthcare Services Mexico
Healthcare Services Mexico increased oncology revenues and reached 12% share in out-of- pocket revenues in December, showing signs of recovery and partially offsetting legacy volume and margin pressures External Revenue1 (S/ Mn, %) Adj. EBITDA and margin1,2 (S/ Mn, %) 24% of LTM Revenues 33% of LTM
Slide 8: Leadership changes and preferred-tier status with key payors
Leadership changes and preferred-tier status with key payors, position Mexico for a return to growth 1. Leadership & Organization 4. Physician Engagement & Productivity ▪ Adjustments to our senior management team, with all ▪ During 4Q25, management reached approximately 250 key roles now in place. p
Slide 9: Peru delivers consistent outperformance and record-low MLR of 48.5%
Peru delivers consistent outperformance and record-low MLR of 48.5% External Revenue1 (S/ Mn, %) Adj. EBITDA and margin1,2 (S/ Mn, %) 44% of LTM Revenues 45% of LTM Adj. EBITDA 21.7% 22.7% 22.4% 21.2% 22.1% +11% 0% +9% +14% 488 489 1,912 +14% 442 1,748 -1% 423 111 109 371 96 4Q’24 3Q’25 4Q’25 FY ’24
Slide 10: Colombia successfully prioritizing cashflow
Colombia successfully prioritizing cashflow, with risk-sharing models now 21% of segment revenue and reduced exposure to intervened payors; unfavorable YoY comparison due to extraordinary items from 4Q24 External Revenue1 (S/ Mn, %) Adj. EBITDA and margin1,2 (S/ Mn, %) 33% of LTM Revenues 22% of LTM
Slide 11: Q4 & FY 2025 Consolidated Results
Q4 & FY 2025 Consolidated Results 11
Slide 12: Consolidated revenues demonstrate consistent upward momentum
Consolidated revenues demonstrate consistent upward momentum as growth in Peru and Colombia successfully offset challenges in Mexico ▪ Peru grew from higher tickets and memberships and demand for network services at high price points ▪ Colombia remained focused on risk-sharing models and payor diver
Slide 13: Consolidated Adjusted EBITDA in 4Q25
Consolidated Adjusted EBITDA in 4Q25 supported by growth in Peru, offset by Mexico´s margin decline due to ISSSTELEON contract and stabilization phase; and by Colombia´s price adjustments and rebates recognized in 4Q24 ▪ Adjusted EBITDA1 -14% FXN YoY with Adjusted EBITDA Margin1 decreasing 4.5 pp Yo
Slide 14: Consolidated Adjusted EBITDA in FY25
Consolidated Adjusted EBITDA in FY25 driven by Peru growth, offset by softer demand and margin decline from government contract in Mexico, and by lower margins in Colombia under cash flow prioritization strategy ▪ FY Adjusted EBITDA1 -3% FXN in YoY with Adjusted EBITDA Margin1 decreasing 1.7 pp YoY
Slide 15: Adjusted Net Income increased to S/136 million in 4Q25
Adjusted Net Income increased to S/136 million in 4Q25 not only as product of non-cash FX gains, but also a reduction in interest expense, net of extraordinary refinancing fees ▪ Net interest expense includes S/170 million in extraordinary costs related to refinancing Adjusted Net Income1 bridge: 4Q
Slide 16: Adjusted Net Income grew to S/336 million in FY25
Adjusted Net Income grew to S/336 million in FY25 as company capitalized on improved financial discipline and debt management, also aided by non-cash FX gains ▪ Net interest expense includes S/170 million in extraordinary costs related to refinancing Adjusted Net Income1 bridge: 2024 vs 2025 (S/ Mn)
Slide 17: Free cash flow expands 35% and EoP Cash increases 42%
Free cash flow expands 35% and EoP Cash increases 42% in FY25, as company maintains healthy liquidity ▪ Free cash flow in 2025 includes Maintenance CapEx of S/145 million, or 3.3% of revenues, while Auna Seguro´s portfolio rebalance added S/76 million ▪ Financing cash flows include S/46 million of e
Slide 18: Completion of USD 825 million debt refinancing
The successful completion of a holistic USD 825 million debt refinancing significantly fortifies capital structure and reduces annual interest expenses Debt Structure Highlights Debt by Type (%) Debt by Currency (%) ✓ Successful debt refinancing for USD$ 825 million, including US$ 365 million of Con
Slide 19: We entered 2026 well-positioned
Peru continues making consistently strong contributions, demonstrating the resilience and robustness of our integrated model. Centro Ambulatorio Trecca will “We entered become the largest outpatient facility in the country, significantly expanding our reach to serve the EsSalud population. 2026 well
Slide 20: 2026 Guidance
“With a 2026 Guidance strengthened capital Revenue1 growth of 12% FXN, within a range of 10% to 14%, driven by sustained commercial momentum and robust operating execution across markets. structure, and a stronger Adjusted EBITDA1 growth of 12% FXN, within a range of 10% to 14%, position in Mexico,
Slide 21: Q&A
Q&A qund
Slide 22: Exhibits
Exhibits qund
Slide 23: Consolidated Balance Sheet
Consolidated Balance Sheet (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Dec-25 Δ Dec-25 Dec-25 Δ Dec-25 Dec-25 Dec-24 Dec-25 Dec-24 (USD) vs Dec-24 (USD) vs Dec-24 Assets Liabilities Current assets Current liabilities Cash and cash equivalents 100 335 236 100
Slide 24: Consolidated Statement of Income (1/2)
Consolidated Statement of Income (1/2) (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) 4Q'25 Δ 4Q'25 vs Δ FY 25 vs 4Q'25 FY 25 (USD) 4Q'24 FY 24 Revenue Healthcare Services Mexico 77 258 1,039 -4% -13% Healthcare Services Colombia 115 385 1,435 9% -1% - Healthca
Slide 25: Consolidated Statement of Income (2/2)
Consolidated Statement of Income (2/2) (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) 4Q'25 Δ 4Q'25 vs Δ FY 25 vs 4Q'25 FY 25 (USD) 4Q'24 FY 24 Share of profit of equity accounted investees 1 2 10 2% 18% Profit (loss) before tax -27 (91) 199 -3.4x 0.1x Income t
Slide 26: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) FY 25 Δ FY 25 vs FY 25 Δ FY 25 vs FY 25 FY 24 FY 25 FY 24 (USD) FY 24 (USD) FY 24 Cash flows from operating activities Cash flows from investing activities (Loss) profit for the per
Slide 27: Adjusted EBITDA and Adjusted EBITDA Margin reconciliation
Adjusted EBITDA and Adjusted EBITDA Margin reconciliation (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Adjusted EBITDA: is calculated as profit (loss) before tax for the period plus net finance cost, depreciation and amortization, pre- operating expenses for
Slide 28: Adjusted EBITDA reconciliation continued
Adjusted EBITDA and Adjusted EBITDA Margin reconciliation (continued) (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) For the three months ended December 31, 2025 Healthcare Consolidated Healthcare Healthcare Oncosalud Holding and Services Reportable Services Me
Slide 29: Adjusted EBITDA reconciliation continued
Adjusted EBITDA and Adjusted EBITDA Margin reconciliation (continued) (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Year to date December 31, 2025 Healthcare Consolidated Healthcare Healthcare Oncosalud Holding and Services Reportable Services Mexico Services
Slide 30: Consolidated Peru Adjusted EBITDA reconciliation
Consolidated Peru Adjusted EBITDA and Adjusted EBITDA Margin reconciliation (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Consolidated Peru Adjusted EBITDA: is calculated by adding Healthcare Services Peru Segment Adjusted EBITDA plus Oncosalud Peru Segment Ad
Slide 31: Adjusted Net Income reconciliation
Adjusted Net Income reconciliation (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Adjusted Net Income: is calculated as profit (loss) for the period plus adjustments as described below. 4Q'25 4Q'25 4Q'24 FY 25 FY 24 (USD) Net Income (Loss) (19) (64) 24 111 124
Slide 32: Free Cash Flow
Free Cash Flow (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Free Cash Flow: is calculated by adding Net Cash Flows from Operations and Net Cash Flows used in Investment activities. 2024 2025 Cash from Operating Activities 841,778 856,434 (-) Income t ax 194,3
Slide 33: Adjusted Basic and Diluted Earnings per Share
Adjusted Basic and Diluted Earnings per Share (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Adjusted Basic and Diluted Earnings per Share: Adjusted Basic and Diluted Earnings per Share is calculated by dividing profit attributable to owners of Adjusted Net Inc
Slide 34: Net Debt reconciliation
Net Debt reconciliation (Figures in millions of Soles, unless expressed otherwise) Net Debt: We calculate Net Debt as Gross Debt minus Cash and cash equivalents. Dec-24 Dec-25 (+) Loans and borrowings 3,620 3,533 Short t erm debt 654 316 Long t erm debt 2,966 3,216 (+) Lease Liabilities 148 124 Gros
Slide 35: Leverage Ratio reconciliation
Leverage Ratio reconciliation (Figures in millions of Soles, unless expressed otherwise) Leverage Ratio: is calculated as (i) current and non-current loans and borrowings plus current and non-current lease liabilities minus (ii) cash and cash equivalents, divided by (iii) Last twelve months Adjusted
Slide 36: Key Operational Metrics – Oncosalud Peru & Healthcare Services
Key Operational Metrics – Oncosalud Peru & Healthcare Services 1) As of period end and as reported to the National Superintendence of Health Susalud. Includes Oncology plans and Health plans. 2) Includes active plan members and inactive members. Inactive members are defined as Δ FY 25 vs those plan
Slide 37: Trends in Key Financial Metrics
Trends in Key Financial Metrics (Figures in millions of Soles, unless expressed otherwise) 4Q'23 1Q'24 2Q'24 3Q'24 4Q'24 1Q'25 2Q'25 3Q'25 4Q'25 Revenue Oncosalud Peru 244 253 269 273 276 281 286 294 304 Healthcare Services Peru 225 241 255 255 245 263 269 279 273 Healthcare Services Colombia 335 34
Slide 38: Investor Relations
Investor Relations contact@aunainvestors.com www.aunainvestors.com 38